Literature DB >> 31471598

Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA.

Shu Yi Shen1, Justin M Burgener1,2, Scott V Bratman1,2,3, Daniel D De Carvalho4,5.   

Abstract

Circulating cell-free DNA (cfDNA) comprises small DNA fragments derived from normal and tumor tissue that are released into the bloodstream. Recently, methylation profiling of cfDNA as a liquid biopsy tool has been gaining prominence due to the presence of tissue-specific markers in cfDNA. We have previously reported cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) as a sensitive, low-input, cost-efficient and bisulfite-free approach to profiling DNA methylomes of plasma cfDNA. cfMeDIP-seq is an extension of a previously published MeDIP-seq protocol and is adapted to allow for methylome profiling of samples with low input (ranging from 1 to 10 ng) of DNA, which is enabled by the addition of 'filler DNA' before immunoprecipitation. This protocol is not limited to plasma cfDNA; it can also be applied to other samples that are naturally sheared and at low availability (e.g., urinary cfDNA and cerebrospinal fluid cfDNA), and is potentially applicable to other applications beyond cancer detection, including prenatal diagnostics, cardiology and monitoring of immune response. The protocol presented here should enable any standard molecular laboratory to generate cfMeDIP-seq libraries from plasma cfDNA in ~3-4 d.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31471598     DOI: 10.1038/s41596-019-0202-2

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  1 in total

1.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

Authors:  S Jahr; H Hentze; S Englisch; D Hardt; F O Fackelmayer; R D Hesch; R Knippers
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

  1 in total
  27 in total

1.  Cancer Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA.

Authors:  Jinyong Huang; Alex C Soupir; Brian D Schlick; Mingxiang Teng; Ibrahim H Sahin; Jennifer B Permuth; Erin M Siegel; Brandon J Manley; Bruna Pellini; Liang Wang
Journal:  Cancers (Basel)       Date:  2021-11-09       Impact factor: 6.639

2.  Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer.

Authors:  Eddie Adams; Gregory D Sepich-Poore; Sandrine Miller-Montgomery; Rob Knight
Journal:  View (Beijing)       Date:  2022-01-31

3.  Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.

Authors:  Jacob E Berchuck; Sylvan C Baca; Heather M McClure; Keegan Korthauer; Harrison K Tsai; Pier Vitale Nuzzo; Kaitlin M Kelleher; Monica He; John A Steinharter; Soumya Zacharia; Sandor Spisak; Ji-Heui Seo; Vincenza Conteduca; Olivier Elemento; Joonghoon Auh; Michael Sigouros; Eva Corey; Michelle S Hirsch; Mary-Ellen Taplin; Toni K Choueiri; Mark M Pomerantz; Himisha Beltran; Matthew L Freedman
Journal:  Clin Cancer Res       Date:  2022-03-01       Impact factor: 13.801

4.  DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma.

Authors:  Jeffrey A Zuccato; Vikas Patil; Sheila Mansouri; Jeffrey C Liu; Farshad Nassiri; Yasin Mamatjan; Ankur Chakravarthy; Shirin Karimi; Joao Paulo Almeida; Anne-Laure Bernat; Mohammed Hasen; Olivia Singh; Shahbaz Khan; Thomas Kislinger; Namita Sinha; Sébastien Froelich; Homa Adle-Biassette; Kenneth D Aldape; Daniel D De Carvalho; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2022-03-12       Impact factor: 13.029

5.  HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.

Authors:  Xiaodong Lu; Ka-Wing Fong; Galina Gritsina; Fang Wang; Sylvan C Baca; Lourdes T Brea; Jacob E Berchuck; Sandor Spisak; Jenny Ross; Colm Morrissey; Eva Corey; Navdeep S Chandel; William J Catalona; Ximing Yang; Matthew L Freedman; Jonathan C Zhao; Jindan Yu
Journal:  Nat Genet       Date:  2022-04-25       Impact factor: 41.307

6.  Methylation extends the reach of liquid biopsy in cancer detection.

Authors:  Wenyuan Li; Xianghong Jasmine Zhou
Journal:  Nat Rev Clin Oncol       Date:  2020-11       Impact factor: 66.675

Review 7.  Clinical implementation and current advancement of blood liquid biopsy in cancer.

Authors:  Kazunori Watanabe; Yusuke Nakamura; Siew-Kee Low
Journal:  J Hum Genet       Date:  2021-06-04       Impact factor: 3.172

Review 8.  Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors.

Authors:  Severa Bunda; Jeffrey A Zuccato; Mathew R Voisin; Justin Z Wang; Farshad Nassiri; Vikas Patil; Sheila Mansouri; Gelareh Zadeh
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

9.  Cell-free DNA methylome profiling by MBD-seq with ultra-low input.

Authors:  Jinyong Huang; Alex C Soupir; Liang Wang
Journal:  Epigenetics       Date:  2021-03-16       Impact factor: 4.528

10.  Plasma cell-free DNA methylation combined with tumor mutation detection in prognostic prediction of patients with non-small cell lung cancer (NSCLC).

Authors:  Dan Guo; Liang Yang; Jianwei Yang; Ke Shi
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.